Therapeutic Potential of Alpha-1 Antitrypsin in Type 1 and Type 2 Diabetes Mellitus

被引：13

作者：

Park, Sangmi S. ^{[1
]}

Ortega, Romy Rodriguez ^{[1
]}

Agudelo, Christina W. ^{[1
]}

Perez, Jessica Perez ^{[1
]}

Gandara, Brais Perez ^{[1
]}

Garcia-Arcos, Itsaso ^{[1
]}

McCarthy, Cormac ^{[2
]}

Geraghty, Patrick ^{[1
]}

机构：

[1] State Univ New York Downstate Hlth Sci Univ, Dept Med, Brooklyn, NY 11203 USA

[2] Univ Coll Dublin, Educ & Res Ctr, Sch Med, St Vincents Univ Hosp, Dublin D04 T6F4, Ireland

来源：

MEDICINA-LITHUANIA | 2021年 / 57卷 / 04期

关键词：

alpha-1; antitrypsin; diabetes mellitus; inflammation; apoptosis; PHOSPHOLIPID TRANSFER PROTEIN; ALPHA(1)-ANTITRYPSIN THERAPY; NEUTROPHIL ELASTASE; DOUBLE-BLIND; CATHEPSIN-G; DEFICIENCY; INHIBITOR; GENE; DENSITY; PLASMA;

D O I：

10.3390/medicina57040397

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Alpha-1 antitrypsin (AAT) has established anti-inflammatory and immunomodulatory effects in chronic obstructive pulmonary disease but there is increasing evidence of its role in other inflammatory and immune-mediated conditions, like diabetes mellitus (DM). AAT activity is altered in both developing and established type 1 diabetes mellitus (T1DM) as well in established type 2 DM (T2DM). Augmentation therapy with AAT appears to favorably impact T1DM development in mice models and to affect beta-cell function and inflammation in humans with T1DM. The role of AAT in T2DM is less clear, but AAT activity appears to be reduced in T2DM. This article reviews these associations and emerging therapeutic strategies using AAT to treat DM.

引用

页数：9

共 50 条

[1] Alpha-1 Antitrypsin Therapy in Recent-Onset Type 1 Diabetes
Lebenthal, Yael
Brener, Avivit
Hershkovitz, Eli
Shehadeh, Naim
Shalitin, Shlomit
Gai-Castro, Sharon
Stein, Michal
Tov, Naveh
Rachmiel, Marianna
DIABETES, 2018, 67
[2] Therapeutic potential of alpha-1 antitrypsin in human disease
Kim, Minsun
Cai, Qing
Oh, Youngman
ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2018, 23 (03) : 131 - 135
[3] Alpha-1 antitrypsin therapy is safe and well tolerated in children and adolescents with recent onset type 1 diabetes mellitus
Rachmiel, Marianna
Strauss, Pnina
Dror, Nitzan
Benzaquen, Hadassa
Horesh, Orit
Tov, Nave
Weintrob, Naomi
Landau, Zohar
Ben-Ami, Michal
Haim, Alon
Phillip, Moshe
Bistritzer, Tzvi
Lewis, Eli C.
Lebenthal, Yael
PEDIATRIC DIABETES, 2016, 17 (05) : 351 - 359
[4] ALPHA-1 ANTITRYPSIN OVEREXPRESSING MESENCHYMAL STROMAL CELLS PREVENTS ONSET OF TYPE 1 DIABETES
Wei, H.
Gou, W.
Lotfy, A.
Green, E.
Strange, C.
Wang, H.
CYTOTHERAPY, 2023, 25 (06) : S98 - S98
[5] Therapeutic strategies for Type 1 and Type 2 diabetes mellitus
Giannoukakis, N
Pietropaolo, M
Trucco, M
DIABETES NUTRITION & METABOLISM, 2002, 15 (03) : 173 - 203
[6] Metabolic and immunologic observations from a trial of alpha-1 antitrypsin in recent onset type 1 diabetes
Gottlieb, P.
Michels, A.
Di Domenico, D.
Fitzgerald-Miller, L.
Johnson, K.
Lungaro, J.
Meyers, L.
Conley, A.
Zipris, D.
DIABETOLOGIA, 2012, 55 : S193 - S193
[7] Immunological and homeostatic pathways of alpha-1 antitrypsin: a new therapeutic potential
Mazzuca, Carmen
Vitiello, Laura
Travaglini, Silvia
Maurizi, Fatima
Finamore, Panaiotis
Santangelo, Simona
Rigon, Amelia
Vadacca, Marta
Angeletti, Silvia
Scarlata, Simone
FRONTIERS IN IMMUNOLOGY, 2024, 15
[8] Unmasking the Therapeutic Potential of Biomarkers in Type-1 Diabetes Mellitus
Gupta, Amit
Behl, Tapan
Sehgal, Aayush
Sharma, Sanchay
Singh, Sukhbir
Sharma, Neelam
Garg, Madhukar
BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY, 2021, 11 (05): : 13187 - 13201
[9] Alpha-1 antitrypsin: A novel biomarker and potential therapeutic approach for metabolic diseases
Zhang, Xiaojuan
Ostrov, David A.
Tian, Haoming
CLINICA CHIMICA ACTA, 2022, 534 : 71 - 76
[10] New Therapeutic Targets for Alpha-1 Antitrypsin Deficiency
Lomas, David A.
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2018, 5 (04): : 233 - 243

← 1 2 3 4 5 →